Bifogade filer
Kurs
+4,13%
Prenumeration
Kalender
Est. tid* | ||
2026-02-13 | 08:50 | Bokslutskommuniké 2025 |
2025-08-22 | 08:50 | Kvartalsrapport 2025-Q2 |
2025-06-18 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2025-06-12 | - | Årsstämma |
2025-02-20 | - | Extra Bolagsstämma 2024 |
2025-02-14 | - | Bokslutskommuniké 2024 |
2024-11-08 | - | Kvartalsrapport 2024-Q3 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-05-24 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2024-05-23 | - | Årsstämma |
2024-05-17 | - | Kvartalsrapport 2024-Q1 |
2024-02-16 | - | Bokslutskommuniké 2023 |
2023-11-10 | - | Kvartalsrapport 2023-Q3 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-05-26 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2023-05-25 | - | Årsstämma |
2023-05-12 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-11-11 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-05-20 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2022-05-19 | - | Årsstämma |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-20 | - | Kvartalsrapport 2021-Q2 |
2021-06-07 | - | Split LARK 20:1 |
2021-05-26 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2021-05-25 | - | Årsstämma |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-02-17 | - | Bokslutskommuniké 2020 |
2020-11-13 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-06-30 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2020-06-29 | - | Årsstämma |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-05-17 | - | Kvartalsrapport 2019-Q1 |
2019-05-16 | - | Årsstämma |
2019-05-15 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-04 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2018-05-03 | - | Årsstämma |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-01-29 | - | Bokslutskommuniké 2017 |
2017-11-01 | - | Kvartalsrapport 2017-Q3 |
2017-08-17 | - | Kvartalsrapport 2017-Q2 |
2017-05-18 | - | Kvartalsrapport 2017-Q1 |
2017-05-10 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2017-05-09 | - | Årsstämma |
2017-01-31 | - | Bokslutskommuniké 2016 |
2017-01-26 | - | Extra Bolagsstämma 2017 |
2016-11-17 | - | Kvartalsrapport 2016-Q3 |
2016-08-17 | - | Kvartalsrapport 2016-Q2 |
2016-05-19 | - | Kvartalsrapport 2016-Q1 |
2016-04-05 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
2016-04-04 | - | Årsstämma |
2016-02-18 | - | Bokslutskommuniké 2015 |
2015-11-19 | - | Kvartalsrapport 2015-Q3 |
2015-08-20 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Unique innovation collaboration funded by academia and industry
A 5-year multi-disciplinary collaboration has been launched to develop adeno-associated virus (AAV) based gene therapies, funded by academia and industry. KTH is host for the newly funded Vinnova Innovation Milieu ‘’GeneNova’’.
AAV based gene therapies have potential for curative treatment of a range of serious human diseases. One of the current technology limitations is the high manufacturing costs and limited supply.
A unique collection of world-leading Swedish technology and service providers, pharma companies and university faculties have joined forces to establish the GeneNova collaboration aimed at disrupting the current strategies for the development and bioproduction of these advanced therapies. The shared vision of GeneNova is to innovate and apply novel technological solutions throughout the drug development process.
This collaboration is supported by Sweden’s Innovation agency, Vinnova, and industry partners to just over 110 MSEK total budget 2021-2026.
Partners of GeneNova: Alfa Laval, AstraZeneca, Biotage, CombiGene, Karolinska Institutet, KTH Royal Institute of Technology, Uppsala University, Vironova, Ziccum
Johan Rockberg, professor in antibody technology and directed evolution at KTH Royal Institute of Technology, Stockholm
“I am extremely honored and excited to lead the GeneNova team with such wide representation of experts spanning from hardware, automation, mechanics, AI and mathematics to protein and cell engineering, bioprocess development, separation, drug discovery, neurology, virology, and formulation. Five years from now we aim to be able to look back at how we have contributed with many new perspectives, technologies, and applications of gene therapy development for the benefit of the patients.”
Jan Nilsson, CEO CombiGene:
“At CombiGene, we are proud to be part of this pioneering project. Breaking new ground and removing barriers is at the core of our DNA, and we are thrilled to be collaborating with some of Sweden’s leading experts within academia and industry. AAV based gene therapies represent fantastic opportunities to create new treatments, and if we, on top of that, can develop novel and inexpensive production methods, the benefits would be enormous.”
Contacts
Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com
Bert Junno, Chairman of the board
Phone: +46 (0)707 77 22 09
bert.junno@combigene.com
www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
info@combigene.com
About CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)8 52 80 03 99, info@fnca.se.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714